<DOC>
	<DOC>NCT01331993</DOC>
	<brief_summary>The primary purpose is to demonstrate the bioequivalence of naproxen administered as VIMOVO manufactured at a new facility in Sweden (AstraZeneca) to that of naproxen administered as VIMOVO manufactured in the USA (Patheon) and to a marketed enteric-coated naproxen formulation.</brief_summary>
	<brief_title>A Bioequivalence Study to Compare VIMOVO Manufactured at AstraZenca AB to VIMOVO Manufactured by Patheon Pharmaceuticals and Marketed Enteric-coated Naproxen Formulation</brief_title>
	<detailed_description>A Phase I, Open-label, Randomised, 3-way Crossover Study to demonstrate Bioequivalence of a Single Oral Dose of Naproxen administered as VIMOVO manufactured at AstraZeneca AB compared to that of VIMOVO manufactured by Patheon Pharmaceuticals and a marketed enteric-coated Naproxen Formulation (Manufactured by Roche) in Healthy Volunteers.</detailed_description>
	<mesh_term>Esomeprazole</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<criteria>Healthy male or female volunteer, aged 18 55 years (inclusive) Female volunteers must be nonpregnant and nonlactating and have a negative urine pregnancy test result prior to enrolment into the study. Female volunteers of childbearing potential must be using appropriate birth control during the entire duration of the study Body mass index of = 19 to =30 kg/m2 (inclusive) and weights of = 50 to = 100 kg (inclusive) Volunteer who is likely to have unrecognized cardiovascular or cerebrovascular disease, based on history or risk factors, or who has a clinical significant ECG finding at screening Uncontrolled hypertension defined as resting systolic pressure &gt;140 mmHg or diastolic pressure &gt;90 mmHg at screening or admission to Period 1 Presence or prior history of abnormal bleeding or bleeding disorders, or any volunteer with significant history of peptic ulcer disease or other acid related gastrointestinal symptoms Any gastrointestinal disease, abnormality or gastric surgery that may interfere with gastric emptying, motility and drug absorption</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>crossover</keyword>
	<keyword>bioequivalence</keyword>
	<keyword>naproxen</keyword>
	<keyword>esomeprazole</keyword>
	<keyword>vimovo</keyword>
	<keyword>healthy volunteers</keyword>
</DOC>